A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression [0.03%]
HBG2远端启动子中的一次单碱基治疗性插入重新激活了γ-珠蛋白的表达
Xiuqin Bao,Yuanyi Gao,Xiaoyi Chen et al.
Xiuqin Bao et al.
Background: The reactivation of developmental silenced γ-globin genes (HBG1/2) has shown promise as a therapeutic strategy for improving symptoms of β-hemoglobinopathies. Currently, the focus of therapeutic targets is p...
Lasse Vedel Jørgensen,Emil Birch Christensen,Mike Bogetofte Barnkob et al.
Lasse Vedel Jørgensen et al.
Chimeric antigen receptor (CAR) NK cell therapy has emerged as a promising alternative to CAR T cell therapy, offering significant advantages in terms of safety and versatility. Here we explore the current clinical landscape of CAR NK cells...
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma [0.03%]
乙型肝炎表面抗原：在肝细胞癌中的致癌机制和临床意义
Bingyan Hao,Yachong Liu,Bohan Wang et al.
Bingyan Hao et al.
Liver cancer is the third leading cause of death globally, with hepatitis B virus (HBV) infection being identified as the primary risk factor for its development. The occurrence of HBV-related hepatocellular carcinoma (HCC) is attributed to...
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting [0.03%]
多发性骨髓瘤中对CAR-T细胞治疗抵抗的机制：来自2024年ASH年会的最新更新
Yuhan Hu,Jiangxue Hou,Zhongxing Jiang et al.
Yuhan Hu et al.
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T ...
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway [0.03%]
来自骨髓间充质干细胞的MMP14通过JAK/STAT通路促进急性髓系白血病的进展和Ara-C耐药性
Jinxian Wu,Xinqi Li,Yin Liu et al.
Jinxian Wu et al.
Growing evidence underscores the pivotal impact of crosstalk between leukemic stem cells (LSCs) and mesenchymal stromal cells (MSCs) within their niche on leukemia initiation, progression, and therapy response. Although MMP14 plays an impor...
Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance [0.03%]
急性髓系白血病中dynamin2基因突变的临床特征及预后意义
Kunpeng Luo,Jiayuan Chen,Wenting Wang et al.
Kunpeng Luo et al.
Acute myeloid leukemia (AML) is a highly heterogeneous myeloid malignancy which can be classified by genetic aberrations. To evaluate the impact of the dynamin 2 mutation in AML, we systematically assessed the characteristics and prognostic...
Antibody-drug conjugates in breast cancer: current evidence and future directions [0.03%]
抗体-药物结合物在乳腺癌中的应用：现有证据和未来方向
Ning Li,Lu Yang,Zixuan Zhao et al.
Ning Li et al.
Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers. So far, trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-D...
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone [0.03%]
全功能CRISPR/Cas基因编辑的糖皮质激素受体敲除EBV-gp350-CAR敲入T细胞具有强大功效并对地塞米松有抵抗性
Theresa Kaeuferle,Maximilian Zwermann,Nadine Stoll et al.
Theresa Kaeuferle et al.
Background: Epstein-Barr virus (EBV) reactivation in immunocompromised patients and post-transplantation is associated with morbidity, mortality and with the onset of a variety of malignant diseases. Adoptive T-cell thera...
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012-2021: a systematic analysis [0.03%]
2012-2021年全球33组早期癌症发病率、死亡率和伤残调整寿命年的差异：系统分析
Wenxin Yan,Min Liu,Wenzhan Jing et al.
Wenxin Yan et al.
Background: The global cancer burden is rising, with early-onset cancers becoming more prevalent. We aimed to investigate the burden, trend and population disparity in 33 early-onset cancers from 2012 to 2021. ...
New exploration of KRASG12D inhibitors and the mechanisms of resistance [0.03%]
KRASG12D抑制剂的新探索及抗性机制
Ying Li,Junfeng Zhao,Yintao Li
Ying Li
The development of Kirsten rat sarcoma viral oncogene homologue (KRAS) targeted therapies has been the focus of cancer treatment. The most common mutant subtypes of KRAS driver genes are G12C, G12V, and G12D, and are associated with poor pr...